Interleukin 6 and C-reactive protein in esophageal cancer
Authors:
- Magdalena GroblewskaMGMagdalena Groblewska
- Barbara MroczkoBarbara Mroczko
- Dorota SosnowskaDSDorota Sosnowska
- Maciej SzmitkowskiMSMaciej Szmitkowski
- 1 October 2012
- journal article
- review article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 413 (19-20) , 1583-1590
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort studyBreast Cancer Research, 2011
- Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patientsWorld Journal of Surgical Oncology, 2011
- Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancerClinical and Experimental Medicine, 2010
- Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancerBMC Cancer, 2009
- Cancer-related inflammationNature, 2008
- Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancerBritish Journal of Cancer, 2006
- Inflammation and necrosis promote tumour growthNature Reviews Immunology, 2004
- Inflammation and cancerNature, 2002
- Expression of C-Reactive Protein in the Human Respiratory TractInfection and Immunity, 2001